by The respiratory disease vaccine market size is poised to grow by USD 116.53 billion by 2032 from USD 95.13 billion in 2022, exhibiting a CAGR of 2.05% during the forecast period 2023-2032.
Key Takeaways
- Asia Pacific dominated the market in 2022 with the largest market share of 55% in 2022.
- By Distribution Channel, the hospital segment dominated the market with the highest market of 55% in 2022.
- By Disease Type, the chronic obstructive pulmonary disease (COPD) segment dominated the market in 2022.
- By Type, the viral vaccine segment contributed more than 55% of revenue share in 2022.
- By Type, the bacterial vaccine segment is expected to expand at a significant CAGR during the forecast period.
- By Age Group, the adult segment dominated the market with a major market share of 77% in 2022.
- By Age Group, the pediatric segment is expected to be the most lucrative segment of the market throughout the forecast period.
- By Infection, the COVID-19 segment captured more than 70% of market share in 2022.
- By Infection, the Respiratory Syncytial Virus (RSV) segment is expected to grow at a significant rate during the forecast period.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Respiratory disease vaccine market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Respiratory disease vaccine Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3249
Report Scope of the Respiratory Disease Vaccine Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 97.08 Billion |
| Market Size by 2032 | USD 116.53 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 2.05% |
| Largest Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Disease Type, By Type, By Age Group, and By Infection, By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Chip Resistor Market Size To Rake USD 3.7 Bn By 2032
The empirical study on the global Respiratory disease vaccine market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Respiratory disease vaccine Market. Our market report for the Respiratory disease vaccine market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Top Key Players:
- Sanofi
- GSK plc
- Merck & Co., Inc.
- Pfizer Inc.
- Bavarian Nordic
- EMERGENT
- CSL Limited
- Moderna, Inc.
- Serum Institute of India Pvt. Ltd.
- Sinovac Biotech
Segments Covered in the Report:
Data Sources and Methodology
To gather comprehensive insights on the Global Respiratory disease vaccine Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Respiratory disease vaccine Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Respiratory disease vaccine market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Disease Type
- Chronic Obstructive Pulmonary Disease (COPD)
- Pertussis
- Pneumonia
- Measles
- Diphtheria
By Type
- Viral Vaccine
- Bacterial Vaccine
- Combination Vaccine
By Age Group
- Pediatric
- Adult
By Infection
- COVID-19
- Influenza
- Respiratory Syncytial Virus (RSV)
- Pneumonia
- Others
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Respiratory disease vaccine market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Respiratory disease vaccine market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Respiratory disease vaccine market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Respiratory disease vaccine market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Respiratory Disease Vaccine Market
5.1. COVID-19 Landscape: Respiratory Disease Vaccine Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Respiratory Disease Vaccine Market, By Disease Type
8.1. Respiratory Disease Vaccine Market Revenue and Volume, by Disease Type, 2023-2032
8.1.1. Chronic Obstructive Pulmonary Disease (COPD)
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Pertussis
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Pneumonia
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Measles
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. Diphtheria
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Respiratory Disease Vaccine Market, By Type
9.1. Respiratory Disease Vaccine Market Revenue and Volume, by Type, 2023-2032
9.1.1. Viral Vaccine
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Bacterial Vaccine
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Combination Vaccine
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Respiratory Disease Vaccine Market, By Age Group
10.1. Respiratory Disease Vaccine Market Revenue and Volume, by Age Group, 2023-2032
10.1.1. Pediatric
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Adult
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Respiratory Disease Vaccine Market, By Infection
11.1. Respiratory Disease Vaccine Market Revenue and Volume, by Infection, 2023-2032
11.1.1. COVID-19
11.1.1.1. Market Revenue and Volume Forecast (2020-2032)
11.1.2. Influenza
11.1.2.1. Market Revenue and Volume Forecast (2020-2032)
11.1.3. Respiratory Syncytial Virus (RSV)
11.1.3.1. Market Revenue and Volume Forecast (2020-2032)
11.1.4. Pneumonia
11.1.4.1. Market Revenue and Volume Forecast (2020-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 12. Global Respiratory Disease Vaccine Market, By Distribution Channel
12.1. Respiratory Disease Vaccine Market Revenue and Volume, by Distribution Channel, 2023-2032
12.1.1. Hospital & Retail Pharmacies
12.1.1.1. Market Revenue and Volume Forecast (2020-2032)
12.1.2. Government Suppliers
12.1.2.1. Market Revenue and Volume Forecast (2020-2032)
12.1.3. Others
12.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 13. Global Respiratory Disease Vaccine Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.1.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.1.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.1.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.1.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.1.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.1.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.1.7.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.1.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.1.7.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.7. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.9.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.9.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.10. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.12.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.12.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.12.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.14.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.14.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.14.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.8.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.8.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.10.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.10.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.10.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.11.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.11.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.11.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.8.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.8.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.10.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.10.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.10.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.11.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.11.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.11.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.5.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.5.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.5.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.5.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.5.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.5.8.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.5.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.5.8.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 14. Company Profiles
14.1. Sanofi
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. GSK plc
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Merck & Co., Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Pfizer Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Bavarian Nordic
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. EMERGENT
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. CSL Limited
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Moderna, Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Serum Institute of India Pvt. Ltd.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Sinovac Biotech
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Statistics – Empowering Your Data Insights
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
